NVIC

Spikevax mRNA COVID-19 Vaccine (Age 12 and older)

Published November 10, 2021

On September 11, 2023, the FDA approved an updated mRNA COVID-19 vaccine developed and manufactured by Moderna for use in persons 12 years and older to target the Omicron variant XBB.1.5. 

The Moderna mRNA COVID-19 vaccine containing the original SARS-CoV-2 virus was initially issued an EUA by the FDA in December 2020 for use in persons 18 years of age.  On January 31, 2022, the FDA licensed and granted EUA status to Moderna for SPIKEVAX COVID-19 vaccine for use in persons 18 years of age and older. The FDA also stated that use of SPIKEVAX and the experimental Moderna mRNA COVID-19 vaccine were interchangeable due to having the same formulation.  In August 2022, the FDA authorized use under EUA to Moderna for a bivalent COVID-19 vaccine containing the original SARS-CoV-2 virus and the Omicron BA.4/BA.4 variant in persons 18 years and older.  A bivalent COVID-19 vaccine was also authorized for use in adolescents aged 12 through 17 years in October 2022.  These previously authorized vaccine formulations are no longer available for use in the U.S. 

According to the SPIKEVAX COVID-19 vaccine package insert “The nucleoside-modified mRNA in the Moderna COVID-19 Vaccine is formulated in lipid particles, which enable delivery of the nucleoside-modified mRNA into host cells to allow expression of the SARS-CoV-2 S antigen. The vaccine elicits an immune response to the S antigen, which protects against COVID-19.” 

Each 0.5 ml dose of SPIKEVAX 2023-2024 mRNA COVID-19 vaccine contains 50 mcg of nucleoside modified messenger RNA (mRNA) that encodes the pre-fusion stabilized Spike glycoprotein (S) of SARS-CoV-2 Omicron variant lineage Omicron XBB.1.5. 

Each dose also contains a total lipid content of 1.01 mg (SM-102, polyethylene glycol [PEG 2000 dimyristoyl glycerol [DMG, cholesterol, and 1,2-distearoyl-sn-glycero-3-phosphocholine [DSPC), 0.25 mg tromethamine, 0.021 mg acetic acid, 1.2 mg tromethamine hydrochloride, 43.5 mg sucrose and 0.10 mg sodium acetate trihydrate. The vaccine does not contain a preservative and the vaccine vial stoppers are free of latex.  

The 2023-2024 SPIKEVAX COVID-19 vaccine is approved to be given intramuscularly (IM) as a single dose, at least two months after receipt of a previous COVID-19 vaccine dose. 

The duration of vaccine-acquired immunity from SPIKEVAX COVID-19 vaccine is not known. The vaccine offers only minimal protection against infection and transmission. This means that vaccinated individuals can still become infected with the virus and spread it on to others. 

There is no data available on the co-administration of the SPIKEVAX COVID-19 Vaccine with any other vaccine product.  

Individuals with immunocompromising conditions, including those who take medications that induce immunosuppression may have a decreased immune response to SPIKEVAX COVID-19 vaccine. 

According the SPIKEVAX package insert, data on the safety and effectiveness of the vaccine for use in pregnant women is not known. It is also not known whether the vaccine can be transmitted through breastmilk. 

SPIKEVAX COVID-19 vaccine has not been studied for its potential to cause cancer, genotoxicity or male infertility. 

On September 12, 2023, the CDC’s ACIP voted to approve use of the 50mcg dose of the 2023-2024 SPIKEVAX COVID-19 mRNA vaccine targeting the Omicron variant XBB.1.5 in all persons aged 12 years and older. 

Select disease / vaccine